Guizhou Xinbang Pharmaceutical (002390) Stock Overview
Manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
002390 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Guizhou Xinbang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.30 |
| 52 Week High | CN¥4.31 |
| 52 Week Low | CN¥3.14 |
| Beta | 0.32 |
| 1 Month Change | -2.37% |
| 3 Month Change | -17.09% |
| 1 Year Change | -20.48% |
| 3 Year Change | -35.04% |
| 5 Year Change | -63.54% |
| Change since IPO | -37.29% |
Recent News & Updates
Recent updates
Investor Optimism Abounds Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390) But Growth Is Lacking
Feb 13
Here's Why Guizhou Xinbang Pharmaceutical (SZSE:002390) Can Manage Its Debt Responsibly
Dec 16There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings
Sep 26Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings
Jun 26These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely
May 24Shareholder Returns
| 002390 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.5% | 0.1% | 1.8% |
| 1Y | -20.5% | 18.4% | 30.5% |
Return vs Industry: 002390 underperformed the CN Pharmaceuticals industry which returned 18.4% over the past year.
Return vs Market: 002390 underperformed the CN Market which returned 30.5% over the past year.
Price Volatility
| 002390 volatility | |
|---|---|
| 002390 Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 9.7% |
| 10% least volatile stocks in CN Market | 3.1% |
Stable Share Price: 002390 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002390's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 5,059 | Lingzhong Kong | www.xinbang.com |
Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. The company cardiovascular and cerebrovascular, digestive system, endocrine, tumors and immunomodulatory drugs, blood system drugs, rheumatism and rheumatoid arthritis, urinary system, antipyretic and analgesic, cold medicine, gynecological medications, and anti-infective drugs. It also provides medical services.
Guizhou Xinbang Pharmaceutical Co., Ltd. Fundamentals Summary
| 002390 fundamental statistics | |
|---|---|
| Market cap | CN¥6.33b |
| Earnings (TTM) | CN¥77.12m |
| Revenue (TTM) | CN¥5.73b |
Is 002390 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002390 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.73b |
| Cost of Revenue | CN¥4.80b |
| Gross Profit | CN¥934.87m |
| Other Expenses | CN¥857.76m |
| Earnings | CN¥77.12m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 21, 2026
| Earnings per share (EPS) | 0.041 |
| Gross Margin | 16.31% |
| Net Profit Margin | 1.35% |
| Debt/Equity Ratio | 7.2% |
How did 002390 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 17:22 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guizhou Xinbang Pharmaceutical Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yichi Zhang | China International Capital Corporation Limited |
| Mingfang Zhang | Everbright Securities Co. Ltd. |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |